Corporate Profile

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States focused on bringing transformative medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders to patients in China and around the world. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

10 Years of Excellence

Ten years of innovation, collaboration and a shared commitment to improving patient care has shaped Zai Lab into a fully integrated and innovative global biopharmaceutical company.

Explore our journey
INVESTOR HIGHLIGHTS
Corporate Mission

Corporate Mission

Defining our Purpose
Investor Presentation

Investor Presentation

Explore our investor deck
Our Pipeline

Our Pipeline

Explore our pipeline

Event Calendar

View All Events

Dec 03 - Dec 05, 2024

Citi's 2024 Global Healthcare Conference
Latest News
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
Oct 29, 2024
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
Oct 24, 2024
Zai Lab Announces Participation in November and December Investor Conferences
Oct 18, 2024
More News
Stock Quote

2024年 11月 06日 5:47 PM EST

Nov 6, 2024 5:47 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2024年 11月 06日 5:47 PM EST

Nov 6, 2024 5:47 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2024年 11月 06日 5:47 PM EST

Nov 6, 2024 5:47 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

2024年 11月 06日 5:47 PM EST

Nov 6, 2024 5:47 PM EST

  • Volume
  • Day Low/High /
  • 52 - Week Low/High /

Minimum 15 minutes delayed.
Source:


Zai Lab Limited effected a one-to-ten share subdivision effective as of March 30, 2022 (the “Share Subdivision”). Pursuant to the Share Subdivision, each Ordinary Share of the Company was subdivided into ten ordinary shares, and each American Depositary Share (ADS) of the Company now represents ten Ordinary Shares of the Company. If you hold Ordinary Shares of the Company, such as those traded on the Hong Kong Stock Exchange, the number of Ordinary Shares that you held before the Share Subdivision has increased tenfold as a result of the Share Subdivision (therefore if you held 100 Ordinary Shares prior to the Share Subdivision, you now hold 1,000 Ordinary Shares). If you hold ADSs of the Company, such as traded through NASDAQ, the number of ADSs that you held before the Share Subdivision did not change as a result of the Share Subdivision (therefore if you held 100 ADSs prior to the Share Subdivision, you continue to hold 100 ADSs).

Investor & Media Contacts

Woman looking at phone

Investor Inquiries

Christine Chiou, SVP, Head of Investor Relations
+1 (917) 886-6929
christine.chiou1@zailaboratory.com


Lina Zhang, VP, Corporate Strategy and Capital Markets
lina.zhang@zailaboratory.com

Video Camera

Media Inquiries
Shaun Maccoun, Executive Director, Global Communications
+1 (415) 317-7255
shaun.maccoun@zailaboratory.com
 
Xiaoyu Chen, Executive Director, Regional Communications
xiaoyu.chen@zailaboratory.com